Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
NCT00072787
Completed
The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients. The purpose of the phase 2 portion of the study is to determine the antitumor activity of the S-1 and cisplatin regimen established from phase 1 in patients with advanced gastric cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Rosen, Lee, Los Angeles, California +10 locations
Conditions: Gastric Cancer
Register for Updates
Evaluating Patients With Varying Degrees of Renal Function
NCT00398307
Completed
This is a Phase I, open-label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of renal function. Patients will be stratified by baseline 24-hour creatinine clearance(CrCL) into 4 cohorts using the normal clearance formula: Group A: Control Group B:Mild renal dysfunction Group C:Moderate renal function and Group D: Severe renal dysfunction. Six patients will be enrolled into each cohort.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Premiere Oncology of Arizona, Scottsdale, Arizona +8 locations
Conditions: Renal Impairment
Register for Updates
Evaluating Patients With Impaired Hepatic Function
NCT00398424
Completed
This is a Phase I, Open-Label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of hepatic function defined by the NCI classification for hepatic impairment. Patients will be stratified into 4 Cohorts- Normal, Mild, Moderate or Severe. Six patients will be enrolled inot each cohort and receive S-1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Premiere Oncology of Arizona, Scottsdale, Arizona +5 locations
Conditions: Impaired Hepatic Function
Register for Updates
A Safety and Efficacy Study in Patients With Gastric Cancer
NCT00400179
Completed
This is an open-label, international, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1/cisplatin versus 5-FU/cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1) to S-1/cisplatin (experimental arm) or 5-FU/cisplatin (control arm). Patients will be stratified by number of metastatic sites (one vs. more than one), locally advanced or metastatic disease, prior ad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Clearview Cancer Center, Huntsville, Alabama +32 locations
Conditions: Gastric Cancer
Register for Updates
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
NCT04747470
Terminated
This study is planned to be conducted in 2 parts: Part 1: Dose Escalation and Part 2: Safety Run-In and Randomized Expansion. The primary objectives of Part 1 are 1) To characterize the safety and tolerability of GS-3583 as monotherapy in participants with advanced solid tumors. 2) To determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of GS-3583 as monotherapy in participants with advanced solid tumors. The primary objectives of Part 2 is to assess the safety and tol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: START Midwest, Grand Rapids, Michigan +3 locations
Conditions: Advanced Solid Tumors
Register for Updates
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
NCT03040999
Completed
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: UCLA Medical Center ( Site 0273), Los Angeles, California +150 locations
Conditions: Head and Neck Neoplasms
Register for Updates
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
NCT02641093
Active Not Recruiting
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by radiation for 6 weeks. Some patients may also receive cisplatin as standard of care once a week for 6 weeks if the cancer is found to be "high risk". High risk includes cancer that was not completely removed (positive marg... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky +5 locations
Conditions: Head and Neck Cancer
Register for Updates
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
NCT02177695
Completed
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +565 locations
Conditions: Bladder Cancer
Register for Updates
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
NCT05932199
Recruiting
Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM. Primary Objectives: The primary objective is to test whether the combination of platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves recurrence-free survival for patients with resectable MPM compared to historical, published data for surgery with chemotherapy. Secondary Obje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2024
Locations: Duke Cancer Institute, Durham, North Carolina +1 locations
Conditions: Mesothelioma
Register for Updates
Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer
NCT02891447
Completed
This phase II trial studies how well heated mitomycin and cisplatin during surgery work in treating patients with stomach or gastroesophageal cancer. Drugs used in chemotherapy, such as mitomycin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Register for Updates
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
NCT03421353
Completed
This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with advanced, solid tumours and subsequently in patients with non-small-cell lung cancer (NSCLC)
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/19/2024
Locations: Research Site, Lafayette, Indiana +5 locations
Conditions: Advanced Solid Tumours
Register for Updates
QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.
NCT03520686
Active Not Recruiting
This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2024
Locations: Alaska Urological Institute - Alaska Clinical Research Center, Anchorage, Alaska +30 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates